i agree with you and i don't...i fully understand how the investment process with a biotech company looks like...i agree on Lympro that we are close to revenues but i do not expect Lympro to really deliver cash flow for the company unless they have a relly BIG partner ....with MNAF i'm much more confident because of the different indications...with orphan status the company has a very good position to negotiate with BP for BIG money as well imo...so to mee today's news are much more relevant than the Lympro results...in any case the pps is a STEAL at the moment